TrialESMO open2024

Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B.

F Marmé et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.